Entero Healthcare Solutions Limited
NSE: ENTERO · Pharmacy Retail
Snapshot
Unlock Entero Healthcare Solutions Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Entero Healthcare Solutions Limited is a pharmaceutical distributor that supplies medical products, surgical equipment, and vaccines to retail pharmacies, hospitals, and clinics across India. The company operates as a comprehensive supply chain partner within the healthcare ecosystem.
Business Model
The company generates revenue through the wholesale trading and distribution of pharmaceutical products, medical devices, and nutraceuticals. It acts as an intermediary between manufacturers and healthcare providers, leveraging a widespread distribution network.
Growth Outlook
Growth is driven by the increasing demand for organised pharmaceutical distribution in India and the expansion of the company's product portfolio. The company aims to scale its reach to more healthcare providers and retail pharmacies nationwide.
Key Risks
- Regulatory Compliance. Changes in pharmaceutical pricing policies and drug distribution regulations in India could adversely impact profit margins.
- Supply Chain Disruptions. Dependence on timely procurement from manufacturers makes the company vulnerable to supply chain bottlenecks or inventory shortages.
- Intense Competition. The pharmaceutical distribution sector is highly fragmented and competitive, with pressure from both traditional wholesalers and emerging e-pharmacy platforms.
- Working Capital Intensity. The business model requires significant working capital to manage inventory levels and credit cycles with hospitals and pharmacies.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Entero Healthcare Solutions Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹6,591 Cr
TTM · consolidated
NET PROFIT
₹146 Cr
TTM · consolidated
EPS
₹26.44
TTM · consolidated
RETURN ON EQUITY
8.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
2.0%
TTM · standalone
P/E
45.6x
Q4 FY26 · consolidated
EV/EBITDA
19.9x
Q4 FY26 · consolidated
EBITDA MARGIN
4.3%
TTM · consolidated
NET PROFIT MARGIN
2.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmacy Retail
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Entero Healthcare Solutions LimitedENTERO | 5,289 | 45.59 | 19.87 | 29.3% | 4.3% | 8.5% | 2.0% | +0.9% |
MedPlus Health Services LimitedMEDPLUS | 10,004 | 44.16 | 14.02 | 12.3% | 9.8% | 12.2% | 13.7% | -12.7% |
Sastasundar Ven.SASTASUNDR | 890 | 763.78 | — | 18.8% | 0.5% | -0.2% | -24.3% | — |
As of Q4 FY26
Financials
Entero Healthcare Solutions Limited
NSE: ENTERO · Pharmacy Retail
Snapshot
Unlock Entero Healthcare Solutions Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Entero Healthcare Solutions Limited is a pharmaceutical distributor that supplies medical products, surgical equipment, and vaccines to retail pharmacies, hospitals, and clinics across India. The company operates as a comprehensive supply chain partner within the healthcare ecosystem.
Business Model
The company generates revenue through the wholesale trading and distribution of pharmaceutical products, medical devices, and nutraceuticals. It acts as an intermediary between manufacturers and healthcare providers, leveraging a widespread distribution network.
Growth Outlook
Growth is driven by the increasing demand for organised pharmaceutical distribution in India and the expansion of the company's product portfolio. The company aims to scale its reach to more healthcare providers and retail pharmacies nationwide.
Key Risks
- Regulatory Compliance. Changes in pharmaceutical pricing policies and drug distribution regulations in India could adversely impact profit margins.
- Supply Chain Disruptions. Dependence on timely procurement from manufacturers makes the company vulnerable to supply chain bottlenecks or inventory shortages.
- Intense Competition. The pharmaceutical distribution sector is highly fragmented and competitive, with pressure from both traditional wholesalers and emerging e-pharmacy platforms.
- Working Capital Intensity. The business model requires significant working capital to manage inventory levels and credit cycles with hospitals and pharmacies.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Entero Healthcare Solutions Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹6,591 Cr
TTM · consolidated
NET PROFIT
₹146 Cr
TTM · consolidated
EPS
₹26.44
TTM · consolidated
RETURN ON EQUITY
8.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
2.0%
TTM · standalone
P/E
45.6x
Q4 FY26 · consolidated
EV/EBITDA
19.9x
Q4 FY26 · consolidated
EBITDA MARGIN
4.3%
TTM · consolidated
NET PROFIT MARGIN
2.4%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmacy Retail
As of Q4 FY26